{"id":1577,"date":"2019-01-16T13:23:55","date_gmt":"2019-01-16T12:23:55","guid":{"rendered":"http:\/\/www.nanexa.com\/?p=1577"},"modified":"2019-01-16T13:23:55","modified_gmt":"2019-01-16T12:23:55","slug":"nya-prekliniska-resultat-optimala-for-nex-18-projektet","status":"publish","type":"post","link":"https:\/\/nanexa.com\/sv\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\/","title":{"rendered":"Nya prekliniska resultat optimala f\u00f6r NEX-18 projektet"},"content":{"rendered":"<p>Nyhetsbrev<\/p>\n<p>Uppsala 2019-01-16<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>Nya prekliniska resultat optimala f\u00f6r NEX-18 projektet<\/strong><\/p>\n<p>Nanexa har i dagarna erh\u00e5llit resultat fr\u00e5n en preklinisk farmakokinetisk studie (en s\u00e5 kallad PK-studie) i r\u00e5tta med sitt drug delivery-system PharmaShell<sup>\u00ae<\/sup>. Denna g\u00e5ng har PharmaShell-skalen designats f\u00f6r att ge en kortare fris\u00e4ttning, p\u00e5 runt en vecka, och samtidigt eliminera den initiala fris\u00e4ttningen (den s\u00e5 kallade \u201dbursten\u201d) f\u00f6r att slippa en initial fris\u00e4ttningstopp av l\u00e4kemedlet.<\/p>\n<p>Resultaten fr\u00e5n studien visar tydligt att den nya designen av PharmaShell\u00ae ger en optimal grund f\u00f6r NEX-18 projektet* d\u00e4r just en s\u00e5dan fris\u00e4ttningsprofil efterstr\u00e4vas.<\/p>\n<p>&nbsp;<\/p>\n<p>Nanexas VD David Westberg kommenterar:<\/p>\n<p><em>Vi har redan tidigare visat att vi kan skapa en formulering med begr\u00e4nsad initial fris\u00e4ttning. Att vi nu lyckats eliminera denna koncentrationstopp helt anser vi i Bolaget \u00e4r helt unikt. Vi kan genom detta framsteg avsev\u00e4rt begr\u00e4nsa biverkningar som beror p\u00e5 alltf\u00f6r h\u00f6ga koncentrationer av l\u00e4kemedel i blodet. Att vi samtidigt lyckats skapa en en-veckas dep\u00e5beredning visar p\u00e5 styrkan och flexibiliteten i PharmaShell<sup>\u00ae<\/sup>-plattformen. Vi har nu resultat som st\u00f6djer b\u00e5de korta och l\u00e5nga dep\u00e5beredningar, vilket \u00f6ppnar f\u00f6r flera anv\u00e4ndningsomr\u00e5den.<\/em><\/p>\n<p>&nbsp;<\/p>\n<p>*NEX-18 projektet \u00e4r det produktprojekt som Nanexa driver f\u00f6r att f\u00f6rb\u00e4ttra behandlingen inom leukemiindikationerna MDS\/ AML.<\/p>\n<p>&nbsp;<\/p>\n<p>F\u00f6r mer information kontakta:<\/p>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)<\/p>\n<p>Telefon: 0709 &#8211; 42 83 03<\/p>\n<p>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\">david.westberg@nanexa.se<\/a><\/p>\n<p>www.nanexa.com<\/p>\n<p>&nbsp;<\/p>\n<p>Om Nanexa AB (publ)<\/p>\n<p>Nanexa AB \u00e4r ett nanoteknologiskt drug delivery-f\u00f6retag som fokuserar verksamheten p\u00e5 utvecklingen av PharmaShell<sup>\u00ae<\/sup>som \u00e4r ett nytt och banbrytande drug delivery-system som bed\u00f6ms ha en stor potential inom ett flertal indikationsomr\u00e5den. Inom ramen f\u00f6r PharmaShell<sup>\u00ae<\/sup>har Nanexa samarbetsavtal med bland andra AstraZeneca.<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nyhetsbrev<\/p>\n<p>Uppsala 2019-01-16<\/p>\n<p>\u00a0<\/p>\n<p>Nya prekliniska resultat optimala f\u00f6r NEX-18 projektet<\/p>\n<p>Nanexa har i dagarna erh\u00e5llit resultat fr\u00e5n en preklinisk farmakokinetisk studie (en s\u00e5 kallad PK-studie) i r\u00e5tta med sitt drug delivery-system PharmaShell\u00ae.<\/p>\n<p><a class=\"read-more\" href=\"https:\/\/nanexa.com\/sv\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\/\">L\u00e4s mer<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[7],"tags":[],"class_list":["post-1577","post","type-post","status-publish","format-standard","hentry","category-nyheter"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nya prekliniska resultat optimala f\u00f6r NEX-18 projektet - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nya prekliniska resultat optimala f\u00f6r NEX-18 projektet - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nyhetsbrev Uppsala 2019-01-16 \u00a0 Nya prekliniska resultat optimala f\u00f6r NEX-18 projektet Nanexa har i dagarna erh\u00e5llit resultat fr\u00e5n en preklinisk farmakokinetisk studie (en s\u00e5 kallad PK-studie) i r\u00e5tta med sitt drug delivery-system PharmaShell\u00ae.L\u00e4s mer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta property=\"article:published_time\" content=\"2019-01-16T12:23:55+00:00\" \/>\n<meta name=\"author\" content=\"Anders Johansson\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Skriven av\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anders Johansson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\\\/\"},\"author\":{\"name\":\"Anders Johansson\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/person\\\/d26735c022a71d41737953c23a07692a\"},\"headline\":\"Nya prekliniska resultat optimala f\u00f6r NEX-18 projektet\",\"datePublished\":\"2019-01-16T12:23:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\\\/\"},\"wordCount\":311,\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"articleSection\":[\"Nyheter\"],\"inLanguage\":\"sv-SE\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\\\/\",\"name\":\"Nya prekliniska resultat optimala f\u00f6r NEX-18 projektet - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2019-01-16T12:23:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nya prekliniska resultat optimala f\u00f6r NEX-18 projektet\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/person\\\/d26735c022a71d41737953c23a07692a\",\"name\":\"Anders Johansson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1eee3bf26eba126e14bce6671b99389c3e366b0577f9fa176d41797d92204ff1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1eee3bf26eba126e14bce6671b99389c3e366b0577f9fa176d41797d92204ff1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1eee3bf26eba126e14bce6671b99389c3e366b0577f9fa176d41797d92204ff1?s=96&d=mm&r=g\",\"caption\":\"Anders Johansson\"},\"url\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/author\\\/anders\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nya prekliniska resultat optimala f\u00f6r NEX-18 projektet - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\/","og_locale":"sv_SE","og_type":"article","og_title":"Nya prekliniska resultat optimala f\u00f6r NEX-18 projektet - Nanexa AB","og_description":"Nyhetsbrev Uppsala 2019-01-16 \u00a0 Nya prekliniska resultat optimala f\u00f6r NEX-18 projektet Nanexa har i dagarna erh\u00e5llit resultat fr\u00e5n en preklinisk farmakokinetisk studie (en s\u00e5 kallad PK-studie) i r\u00e5tta med sitt drug delivery-system PharmaShell\u00ae.L\u00e4s mer","og_url":"https:\/\/nanexa.com\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\/","og_site_name":"Nanexa AB","article_published_time":"2019-01-16T12:23:55+00:00","author":"Anders Johansson","twitter_card":"summary_large_image","twitter_misc":{"Skriven av":"Anders Johansson","Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanexa.com\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\/#article","isPartOf":{"@id":"https:\/\/nanexa.com\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\/"},"author":{"name":"Anders Johansson","@id":"https:\/\/nanexa.com\/#\/schema\/person\/d26735c022a71d41737953c23a07692a"},"headline":"Nya prekliniska resultat optimala f\u00f6r NEX-18 projektet","datePublished":"2019-01-16T12:23:55+00:00","mainEntityOfPage":{"@id":"https:\/\/nanexa.com\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\/"},"wordCount":311,"publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"articleSection":["Nyheter"],"inLanguage":"sv-SE"},{"@type":"WebPage","@id":"https:\/\/nanexa.com\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\/","url":"https:\/\/nanexa.com\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\/","name":"Nya prekliniska resultat optimala f\u00f6r NEX-18 projektet - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2019-01-16T12:23:55+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"Nya prekliniska resultat optimala f\u00f6r NEX-18 projektet"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nanexa.com\/#\/schema\/person\/d26735c022a71d41737953c23a07692a","name":"Anders Johansson","image":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/secure.gravatar.com\/avatar\/1eee3bf26eba126e14bce6671b99389c3e366b0577f9fa176d41797d92204ff1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1eee3bf26eba126e14bce6671b99389c3e366b0577f9fa176d41797d92204ff1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1eee3bf26eba126e14bce6671b99389c3e366b0577f9fa176d41797d92204ff1?s=96&d=mm&r=g","caption":"Anders Johansson"},"url":"https:\/\/nanexa.com\/sv\/author\/anders\/"}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/posts\/1577","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/comments?post=1577"}],"version-history":[{"count":2,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/posts\/1577\/revisions"}],"predecessor-version":[{"id":1579,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/posts\/1577\/revisions\/1579"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=1577"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/categories?post=1577"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/tags?post=1577"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}